• 1
    Yanez B, Pearman T, Lis CG, Beaumont JL, Cella D. The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol. 2013;24:1073-1078.
  • 2
    Wang XS, Cleeland CS, Mendoza TR, et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst. 2010;102:732-738.
  • 3
    Minton O, Strasser F, Radbruch L, Stone P. Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set. J Pain Symptom Manage. 2012;43:226-235.
  • 4
    Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
  • 5
    Servaes P, Gielissen MF, Verhagen S, Bleijenberg G. The course of severe fatigue in disease-free breast cancer patients: a longitudinal study. Psychooncology. 2007;16:787-795.
  • 6
    Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30:3687-3696.
  • 7
    Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008;100:1155-1166.
  • 8
    Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center–Community Clinical Oncology Program study of 938 patients from community practices. Cancer. 2004;101:851-857.
  • 9
    Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr. 2004;(32):9-16.
  • 10
    Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19:3385-3391.
  • 11
    Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528-538.
  • 12
    US Food and Drug Administration.Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Accessed July 31, 2012.
  • 13
    Berger AM, Abernethy AP, Atkinson A, et al.NCCN Practice Guidelines in Oncology: Cancer-Related Fatigue. Accessed July 17, 2013.
  • 14
    Howell D, Keller-Olaman S, Oliver TK, et al.A Pan-Canadian Practice Guideline: Screening, Assessment and Care of Cancer-Related Fatigue in Adults With Cancer. Accessed August 21, 2013.
  • 15
    Barsevick AM, Cleeland CS, Manning DC, et al; ASCPRO (Assessing Symptoms of Cancer Using Patient-Reported Outcomes). ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J Pain Symptom Manage. 2010;39:1086-1099.
  • 16
    Anderson KO. Role of cutpoints: why grade pain intensity? Pain. 2005;113:5-6.
  • 17
    Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CC. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manage. 2013;45:1083-1093.
  • 18
    Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277-284.
  • 19
    Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634-1646.
  • 20
    StataCorp LP. Stata Statistical Software, version 11 [computer program]. College Station TX: StataCorp LP; 2009.
  • 21
    Wang XS. Cancer-related fatigue. In: Berger AM, Shuster JL, von Roenn JH, eds. Principles and Practice of Palliative Care and Supportive Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2013:84-95.
  • 22
    Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18:743-753.
  • 23
    Given B, Given CW, Sikorskii A, et al. Establishing mild, moderate, and severe scores for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cut-points? J Pain Symptom Manage. 2008;35:126-135.
  • 24
    Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865-869.
  • 25
    Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116:3513-3520.
  • 26
    Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28:3673-3679.
  • 27
    US Census Bureau.ACS Demographic and Housing Estimates: 2010 American Community Survey 1-year Estimates. Accessed August 21, 2013.
  • 28
    Farrar JT. Cut-points for the measurement of pain: the choice depends on what you want to study. Pain. 2010;149:163-164.
  • 29
    Hirschfeld G, Zernikow B. Variability of “optimal” cut points for mild, moderate, and severe pain: neglected problems when comparing groups. Pain. 2013;154:154-159.